These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 886192)

  • 1. Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.
    Cheever MA; Kempf RA; Fefer A
    J Immunol; 1977 Aug; 119(2):714-8. PubMed ID: 886192
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: II. Comparison of cells cultured with and without tumor to noncultured immune cells.
    Cheever MA; Greenberg PD; Fefer A
    J Immunol; 1978 Dec; 121(6):2220-7. PubMed ID: 152790
    [No Abstract]   [Full Text] [Related]  

  • 3. Syngeneic adoptive immunotherapy and chemoimmunotherapy of a Friend leukemia: requirement for T cells.
    Berenson JR; Einstein AB; Fefer A
    J Immunol; 1975 Jul; 115(1):234-8. PubMed ID: 1080165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy of murine leukemia. VIII. Efficacy of passive serum therapy of Friend leukemia virus-induced disease in immunocompromised mice.
    Genovesi EV; Livnat D; Collins JJ
    J Natl Cancer Inst; 1983 Feb; 70(2):311-22. PubMed ID: 6337292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters.
    Sanfilippo F; Kao KJ; Pizzo SV; Collins JJ
    J Natl Cancer Inst; 1980 Mar; 64(3):547-53. PubMed ID: 6928240
    [No Abstract]   [Full Text] [Related]  

  • 6. Chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro: effect of culture duration on therapeutic efficacy.
    Cheever MA; Greenberg PD; Fefer A
    J Natl Cancer Inst; 1981 Jul; 67(1):169-73. PubMed ID: 6942187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunochemotherapy of transplantable Moloney leukemia with cyclophosphamide and allogeneic spleen lymphocytes and reversal of graft-versus-host disease with alloantiserum.
    Kende M; Keys LD; Gaston M; Goldin A
    Cancer Res; 1975 Feb; 35(2):346-51. PubMed ID: 234033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of a Moloney lymphoma with cyclophosphamide and H-2-incompatible spleen cells.
    Fefer A
    Cancer Res; 1973 Apr; 33(4):641-4. PubMed ID: 4696464
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of established tumor by adoptive immunotherapy with specifically immune T cells.
    Greenberg PD; Cheever MA
    Surv Immunol Res; 1985; 4(4):283-96. PubMed ID: 3879738
    [No Abstract]   [Full Text] [Related]  

  • 10. Adoptive transfer of antiviral resistance by lymphoid cells from mice protected against Friend leukemia virus-induced disease by passive serum therapy.
    Collins JJ; Genovesi EV; Livnat D; Sanfilippo F
    Cancer Res; 1981 Jun; 41(6):2407-15. PubMed ID: 7016314
    [No Abstract]   [Full Text] [Related]  

  • 11. Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.
    Thompson JA; Peace DJ; Klarnet JP; Kern DE; Greenberg PD; Cheever MA
    J Immunol; 1986 Dec; 137(11):3675-80. PubMed ID: 3491145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of leukemia regression in mice by immunotherapeutic transfer of T-lymphocytes.
    Johnson CS; Thurlow SM; Furmanski P
    Cancer Res; 1986 Jan; 46(1):183-9. PubMed ID: 3079585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors related to therapeutic efficacy in adoptive chemoimmunotherapy of a Friend virus-induced lymphoma.
    Fass L; Fefer A
    Cancer Res; 1972 Nov; 32(11):2427-31. PubMed ID: 5082591
    [No Abstract]   [Full Text] [Related]  

  • 14. Models for syngeneic adoptive chemoimmunotherapy of murine leukemias.
    Fefer A; Einstein AB; Cheever MA; Berenson JR
    Ann N Y Acad Sci; 1976; 276():573-83. PubMed ID: 1088388
    [No Abstract]   [Full Text] [Related]  

  • 15. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.
    Cheever MA; Greenberg PD; Fefer A
    Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory.
    Klarnet JP; Matis LA; Kern DE; Mizuno MT; Peace DJ; Thompson JA; Greenberg PD; Cheever MA
    J Immunol; 1987 Jun; 138(11):4012-7. PubMed ID: 3108381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Inhibition of the effect of immunocytotherapy in leukemia in mice under stress and the possibilities of its withdrawal].
    Sukhikh GT
    Biull Eksp Biol Med; 1984 Dec; 98(12):694-6. PubMed ID: 6542442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific adoptive immunotherapy.
    Greenberg PD; Klarnet JP; Kern DE; Okuno K; Riddell S; Cheever MA
    Prog Clin Biol Res; 1989; 288():349-61. PubMed ID: 2785692
    [No Abstract]   [Full Text] [Related]  

  • 19. Cloned helper and cytotoxic T lymphocytes as effector cells in adoptive immunotherapy of murine leukemia.
    Bookman MA; Horak E; de Graaf PW
    Prog Clin Biol Res; 1989; 288():141-9. PubMed ID: 2524069
    [No Abstract]   [Full Text] [Related]  

  • 20. Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies.
    Rosenstein M; Rosenberg SA
    J Natl Cancer Inst; 1984 May; 72(5):1161-5. PubMed ID: 6609266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.